Life Sciences

Alexza uses its proprietary technology to enable faster onset of drugs. Faster onset provides rapid relief of acute and episodic symptoms.

Altus® is focused on accelerating the development and commercialization of protein-based products through our Crystalomics™ technology platform. Crystalomics™ rapidly turns proteins into products resulting in significant market benefits in Therapeutic, Diagnostic, and Industrial applications.

Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties.

Arcadia Biosciences (acquired CMEA portfolio company Anawah) is developing agricultural products to capitalize on opportunities that benefit the environment and enhance human health. The company uses advanced screening, breeding and biotechnology techniques to create value for consumers, processors and farmers.

Arcion Therapeutics Inc. is a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain. Arcion has a pipeline of products being developed for the treatment of painful diabetic neuropathy, post-herpetic neuralgia and other forms of moderate and severe pain.

James N. Campbell, M.D. / CEO
Meyer Building, Suite 5-109
The John Hopkins Hospital
600 N. Wolfe Street
Baltimore, MD 21287
410-614-3856

The vision of Auspex Pharmaceuticals is to be the leading deuteration company with a developing pipeline of best-in-class therapeutics that improve on existing drugs across multiple therapeutic areas.

Bayhill Therapeutics is focused on the translation of research into therapeutics for the treatment of autoimmune diseases. The company has established a therapeutic platform of autoimmune modulators, in-licensed from Stanford University, that address the broad market opportunity of Th1 mediated autoimmune diseases.

BioMimetic Pharmaceuticals, Inc. (BMTI) is a biopharmaceutical company focused on the development, commercialization and ultimate marketing of protein therapeutics for tissue and organ regeneration. The Company's lead technologies are for the healing and restoration of bone and other tissues. Its lead products are based on recombinant human platelet-derived growth factor BB (rhPDGF-BB).

Codexis is leading the way with powerful biocatalysts that integrate biology and chemistry. Codexis makes production of pharmaceuticals, biofuels and industrial products faster, cleaner and less expensive.

E-Markets offers a powerful suite of online tools for the agrifood industry. Their applications eliminate barriers between buyers and sellers, enable information sharing across the agrifood value chain, and streamline back office processes resulting in significant return for our customers.

Ensemble Discovery Corporation is an early stage company founded by scientists and entrepreneurs who have come together to translate fundamental innovation in chemical discovery into products that address significant unmet needs in life science, materials, electronics, and chemical markets.

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients.

InSound has the only FDA approved "extended wear" hearing solution, which is virtually invisible, extremely comfortable, has no batteries to change, no daily inserting and removing, and also offers excellent hearing benefits including increased high frequency amplification, decreased distortion, better localized sound, and reduced feedback and occlusion.

Intellikine, Inc. is developing best-in-class kinase inhibitors to address significant unmet medical needs.

Kalypsys, Inc. is a biopharmaceutical company pioneering an industrialized approach to pathway-based drug discovery. Kalypsys implements discovery programs across a broad number of therapeutic areas using its highly automated and integrated suite of discovery technologies in biology, chemistry and informatics.

Monogram (acquired CMEA portfolio company Virologic) is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases.

Perlegen Sciences, Inc. is a private company that uses high-density, whole-wafer microarray technology in combination with new approaches to sample preparation to scan entire human genomes. The company's first objective is to read 50 different human genomes at a single base resolution, discovering and analyzing the patterns of genetic variation between them.

Phenomix is a forward genetics company focusing on rapid target identification and validation. Phenomix's approach to the identification of pathways important in clinical disease relies on classical genetics coupled to the recent advances of the genome project. Phenomix starts from rapidly generating and screening physiological models to identify the best disease models and then in a single step, discovers and validates the genes that are physiologically relevant. Phenomix combines target discovery, target validation, and generation of relevant models for the disease into one efficient platform.

RAVEN biotechnologies' mission is the rapid, simultaneous discovery of novel cell-surface drug targets, and the antibody therapeutics to regulate them.

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases.

Sorbent Therapeutics is developing a treatment for end stage renal disease patients undergoing dialysis.

Don Joseph, CEO
Sorbent Therapeutics, Inc.
750 E. Bunker Court, Suite 900
Vernon Hills, Il. 60061-1863
847-890-1130 (phone)
847-680-9216 (fax)

SurgiQuest provides medical devices for general surgery.

Developer of a proprietary technology platform in combinatorial materials science to discover and improve materials for the chemical and electronics industries.

Capitalizing on breakthrough synthetic chemistry, Tetraphase Pharmaceuticals is leveraging a dynamic drug engine targeted at several significant disease categories.

VeraLight is a medical instrumentation company that was established in October 2004 as an independent spinout of InLight Solutions to focus on a comprehensive approach to noninvasive diabetes screening.

Visiogen is focused on developing innovative products for cataract and refractive patients. Founded in Irvine, California, in 2001, Visiogen's first commercial application, Synchrony®, a dual-optic intraocular lens and pre-loaded injector, is currently in clinical studies in the U.S. and recently received a CE Mark in Europe.

Developer of new molecular-based technology for enhancing the oral absorption, distribution, and pharmacokinetics of drugs.